-
AT13387: Evidence and Research Context
2026-10-07
AT13387 is presented by APExBIO as a synthetic, orally bioavailable small-molecule Hsp90 inhibitor for cancer biology research. Available product information describes high-affinity Hsp90 binding, activity in A375 melanoma cells, and tumor retention in xenograft models, but these claims are not equivalent to independent clinical evidence. The supplied 2025 norovirus study provides important context for regulated cell death and unconventional protein secretion, yet it does not test AT13387 or Hsp90 inhibition. This overview separates reported findings from interpretation and defines the limits of cross-domain extrapolation.
-
Letrozole as a Translational Lens on Estrogen Biology
2026-10-06
Letrozole is more than a potent non-steroidal aromatase inhibitor: it is a mechanistic probe for connecting estrogen biosynthesis, ERα biology, endocrine feedback, and model-specific phenotypes. This article places the compound in a translational framework, distinguishing supplier-reported properties from peer-reviewed clinical context and outlining how researchers can interpret evidence without overextending it.
-
Forskolin and cAMP: Reading Stem Cell Evidence
2026-10-05
Forskolin is a direct adenylate cyclase activator whose value depends on how cAMP perturbation is separated from lineage-specific signaling. This evidence-focused analysis connects Forskolin research with iPSC-derived retinal ganglion cell studies while clarifying translational limits and assay interpretation.
-
5X Protein Loading Buffer (Reducing) Overview
2026-10-05
APExBIO’s K1164 is a concentrated reducing protein loading buffer described for conventional SDS-PAGE sample preparation. No matched paper evidence is available, so its documented scope is limited to product identity and intended conceptual use.
-
Sulfachloropyridazine: Research Context and Evidence
2026-10-04
Sulfachloropyridazine is a sulfonamide antibacterial agent studied in folate-pathway research and animal infection models. This overview examines its reported mechanism, findings from an Eimeria tenella chicken study, conceptual research applications, evidence strength, and limits on broader interpretation.
-
Neticonazole Hydrochloride: Skin-to-Cancer Evidence
2026-10-03
Neticonazole Hydrochloride is best understood through two separate evidence tracks: established topical antifungal use and exploratory colorectal cancer research. This article maps the compound’s mechanisms, diagnostic context, translational promise, and key limitations without overstating early oncology findings.
-
mTORC1 Oscillations Govern Cell-Cycle Transitions
2026-10-02
Joshi and colleagues show that mTORC1 activity is not constant during proliferation but oscillates from low levels in mitosis and G1 to high levels in S and G2. These phase-specific changes support interphase progression, help cells satisfy the Chk1/Wee1-dependent G2/M checkpoint, and determine how readily autophagy is induced by nutrient limitation or partial mTORC1 inhibition.
-
Annexin V-Cy5 Apoptosis Kit Workflow
2026-10-01
Use the Annexin V-Cy5 Apoptosis Kit as a rapid phosphatidylserine checkpoint in zebrafish microglia, lysosomal-stress, and cell-death studies. Its microscopy and flow cytometry compatibility helps distinguish impaired intracellular digestion from genuine apoptosis without treating one endpoint as a substitute for the other.
-
Tomivosertib: From Target Engagement to AML Biology
2026-10-01
Tomivosertib is a highly selective MNK1 inhibitor for investigating eIF4E-dependent biology in acute myeloid leukemia. This article connects biochemical target engagement with AML viability, progenitor assays, combination design, and more rigorous interpretation of MNK-eIF4E data.
-
Neticonazole Hydrochloride: Research Workflows
2026-09-30
Neticonazole Hydrochloride supports a practical antifungal workflow and an exploratory oncology workflow centered on exosome inhibition in cancer. This guide connects direct Candida diagnostics, controlled cell assays, Bcl-2/Bax readouts, and troubleshooting strategies without overstating the maturity of the colorectal cancer evidence.
-
G-1: Selective GPR30 Agonist Workflows
2026-09-30
G-1 enables researchers to isolate GPR30 signaling from classical estrogen-receptor activity in calcium, migration, cardiac, and neural assays. This practical guide connects product properties with concentration planning, cell-type-specific controls, reference-study insights, and troubleshooting strategies.
-
Masitinib (AB1010): Practical Research Workflow
2026-09-29
Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for controlled studies of KIT, PDGFRα, PDGFRβ, KIT-mutant cells, and mast-cell responses. It is appropriate for targeted cancer and mastocytosis research, but not for aqueous or ethanol-based assays, broad-spectrum kinase profiling, or clinical treatment decisions.
-
Sucrose in Freeze-Dried mRNA-LNP Formulations
2026-09-29
Sucrose can do more than protect biomolecules during drying: it can help preserve the physical integrity and functional performance of mRNA–lipid nanoparticles. This article translates recent drying science into practical formulation, process, and analytical decisions for sucrose-containing nucleic acid products.
-
Insulin–AMPK Control of Pink1 mRNA in Neurons
2026-09-28
A neuronal preprint proposes that insulin signaling regulates mitochondrial Pink1 mRNA localization by inhibiting AMPK, which otherwise supports the RNA-anchoring interaction between SYNJ2BP and SYNJ2. The findings connect this localization switch to PINK1 activity and suggest that insulin resistance, including an APOE4-associated model, may impair mitochondrial quality control in neurites.
-
ONX-0914 (PR-957) Assay Design Guide
2026-09-27
This scenario-driven guide explains how to use ONX-0914 (PR-957), SKU A4011, to investigate LMP7-dependent immune modulation without confusing target engagement with cell viability. It covers assay controls, compound handling, interpretation, and evidence-based supplier selection.